Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%

MT Newswires Live06-25

Inoviq (ASX:IIQ) said its CAR-exosome platform showed "strong" in vitro tumor-killing activity in ovarian cancer cell lines, adding to the platform's potential in oncology therapy, according to a Thursday filing with the Australian bourse.

The CAR-exosomes eliminated up to 90% of ovarian cancer cells within 48 hours in a study that evaluated their in vitro efficacy, per the filing.

The CAR-exosome platform has now demonstrated positive in vitro tumor-killing activity across multiple hard-to-treat cancers, including triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, the company said.

Inoviq shares fell nearly 4% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646826580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646826580","market":"us","top_or_hot":-1,"title":"Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> Inoviq (ASX:IIQ) said its CAR-exosome platform showed \"strong\" in vitro tumor-killing activity in ovarian cancer cell lines, adding to the platform's potential in oncology therapy, according to a Thursday filing with the Australian bourse.</p><p>The CAR-exosomes eliminated up to 90% of ovarian cancer cells within 48 hours in a study that evaluated their in vitro efficacy, per the filing.</p><p>The CAR-exosome platform has now demonstrated positive in vitro tumor-killing activity across multiple hard-to-treat cancers, including triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, the company said.</p><p>Inoviq shares fell nearly 4% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-25 11:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Inoviq (ASX:IIQ) said its CAR-exosome platform showed \"strong\" in vitro tumor-killing activity in ovarian cancer cell lines, adding to the platform's potential in oncology therapy, according to a Thursday filing with the Australian bourse.</p><p>The CAR-exosomes eliminated up to 90% of ovarian cancer cells within 48 hours in a study that evaluated their in vitro efficacy, per the filing.</p><p>The CAR-exosome platform has now demonstrated positive in vitro tumor-killing activity across multiple hard-to-treat cancers, including triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, the company said.</p><p>Inoviq shares fell nearly 4% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2646826580","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646826580","pubTimestamp":1782359493,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Inoviq  said its CAR-exosome platform showed \"strong\" in vitro tumor-killing activity in ovarian cancer cell lines, adding to the platform's potential in oncology therapy, according to a Thursday filing with the Australian bourse.The CAR-exosomes eliminated up to 90% of ovarian cancer cells within 48 hours in a study that evaluated their in vitro efficacy, per the filing.The CAR-exosome platform has now demonstrated positive in vitro tumor-killing activity across multiple hard-to-treat cancers, including triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, the company said.Inoviq shares fell nearly 4% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","IIQ.AU":"INOVIQ LTD","BK4230":"旅客陆运","CAR":"安飞士","BK4022":"陆运"},"translate_title":"Inoviq称CAR-Exosome平台在卵巢癌中显示出体外肿瘤杀伤活性；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"IIQ.AU":1},"content_text":"Inoviq (ASX:IIQ) said its CAR-exosome platform showed \"strong\" in vitro tumor-killing activity in ovarian cancer cell lines, adding to the platform's potential in oncology therapy, according to a Thursday filing with the Australian bourse.The CAR-exosomes eliminated up to 90% of ovarian cancer cells within 48 hours in a study that evaluated their in vitro efficacy, per the filing.The CAR-exosome platform has now demonstrated positive in vitro tumor-killing activity across multiple hard-to-treat cancers, including triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, the company said.Inoviq shares fell nearly 4% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646826580","isCrawlerRequest":true}